康恩贝子公司吸入用复方异丙托溴铵溶液获得药品注册证书

Core Viewpoint - Kang En Bei (600572) announced the approval of its inhaled compound ipratropium bromide solution by the National Medical Products Administration, indicating a significant advancement in its product portfolio for treating airway obstructive diseases [1] Group 1 - The product is intended for patients requiring multiple bronchodilators for the treatment of reversible bronchospasm related to airway obstructive diseases [1]